Medical Oncology

Gastric/GEJ Cancer

Questions discussed in this category

What are your top takeaways from ASCO GI 2025?

8 Answers available

Would you offer zolbetuximab in a non-Asian population?

Neither GLOW nor SPOTLIGHT showed a statistically significant improvement in PFS/OS for non-Asian subgroups. It is reasonable to suspect that any PFS/...

1 Answer available

Would you offer zolbetuximab + chemotherapy in a presumed metastatic duodenal bulb adenocarcinoma with 80% Claudin18.2 expression?

Anatomically, the primary tumor is in the duodenum but extends into the gastric pylorus. Would Zolbetuximab be reasonable to offer with FOLFOX, rather...

2 Answers available

How are you sequencing immunotherapy with zolbetuximab in locally advanced/metastatic GEJ cancer when CPS >5 and Claudin 18.2+ (>75%)?

With first line approvals in both FOLFOX/Nivo and FOLFOX/zolbetuximab, how are you sequencing treatment if both CPS/Claudin markers are adequate to tr...

1 Answer available

How would you treat newly diagnosed stage IV GEJ adenocarcinoma with both Claudin 18.2 and HER2 (3+ via IHC) overexpression?

Previously untreated, stage IV GE junction adenocarcinoma with overexpression of HER2 (3+ via IHC) as well as Claudin 18.2. What is the best approach,...

2 Answers available

What are your top takeaways from ASCO GI 2023?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...

8 Answers available

How would you approach a patient with Stage III gastric cancer and poor performance status who had large residual disease (ypT4N1) after neoadjuvant capecitabine and was later found to be MSI-H?

The ICI adjuvant data we have so far doesn't clearly separate MSI-H disease from all comers.

2 Answers available

What are your top takeaways in GI Cancers from ASCO 2023?

6 Answers available

Do you repeat molecular testing at progression in gastric/GEJ tumors or is the initial pathology sufficient for entire treatment course?

Do you rebiopsy or use a liquid assay?

3 Answers available

Papers discussed in this category

J Clin Oncol, 2022 Nov 15

Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.

The New England journal of medicine, 2013-10-31

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

N. Engl. J. Med.,

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Lancet, 2021 Jun 05

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Eur J Cancer, 2018 Aug 24

A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.

NEJM Evidence, 2022 Jun 1

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

N Engl J Med, 2023 Jun 04

Preoperative Treatment of Locally Advanced Rectal Cancer.

Lancet Oncol, 2021 May 04

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.

Lancet Oncol, 2023 Jun 02

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.

Future oncology (London, England), 2022 May 10

MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.

J. Clin. Oncol., 2019 Sep 12

Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.

JAMA Oncol,

Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.

Nature medicine, 2023 Jul 31

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.

Lancet (London, England), 2023 Apr 15

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-10

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

N. Engl. J. Med., 2019 Sep 30

Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer.

N Engl J Med,

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

JAMA oncology, 2020 Jul 01

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.

Lancet (London, England), 2005 Jan 8-14

Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation.

Related Topics in Medical Oncology